The global cancer immunotherapy market size is expected to reach USD 264.63 Billion by 2032, exhibiting the CAGR of 8.7% during the forecast period.
The global cancer immunotherapy market is one of the fastest-growing segments in oncology, with the development of new therapies revolutionizing cancer treatment. Cancer immunotherapy harnesses the power of the body’s immune system to fight cancer cells. Unlike traditional therapies, such as chemotherapy and radiation, which target cancer cells directly, immunotherapy works by stimulating or enhancing the immune system’s natural ability to recognize and destroy tumor cells.
Market Growth Drivers
- Rising Cancer Incidence: The increasing number of cancer cases globally is a major driver for the market. According to the World Health Organization (WHO), cancer is one of the leading causes of death worldwide. The rise in lifestyle-related cancers, such as lung, liver, and colorectal cancers, is particularly contributing to the need for more advanced treatment options like immunotherapy.
- Technological Advancements in Immuno-Oncology: Significant advancements in immunotherapy technologies, including checkpoint inhibitors, CAR-T cell therapies, and monoclonal antibodies, have expanded treatment options for cancer patients. These therapies are more targeted, specific, and effective than traditional methods, offering hope for more difficult-to-treat cancers.
- Government Support and Funding: Governments and regulatory bodies have been actively supporting cancer immunotherapy research and development. Initiatives, such as funding for clinical trials and fast-track approval for promising immuno-oncology drugs, are accelerating the pace of innovation.
Download Free Sample PDF Copy of the Report:
Some of the major players operating in the global market include:
- Amgen Inc.
- Astellas Pharma Inc.
- AstraZeneca
- Bayer AG
- Bristol Myers Squibb
- Eli Lilly
- F. Hoffmann-La Roche Ltd
- Merck KGaA
- Novartis AG
- OSE Immunotherapeutics
Key Trends in the Cancer Immunotherapy Market
- Adoption of Combination Therapies: One of the most significant trends in the cancer immunotherapy market is the shift towards combination therapies. Researchers are investigating how combining immunotherapies with chemotherapy, targeted therapies, and radiation can enhance the effectiveness of cancer treatments. Clinical trials are increasingly focused on identifying optimal combinations to improve patient outcomes.
- Rise of CAR-T Cell Therapies: Chimeric Antigen Receptor T-cell (CAR-T) therapies are revolutionizing the treatment of hematologic cancers, including leukemia and lymphoma. CAR-T cell therapy involves modifying a patient’s own T cells to attack cancer cells more effectively. This cutting-edge technology is expected to see continued growth and is increasingly being studied for solid tumors.
- Immune Checkpoint Inhibitors (ICIs): ICIs, such as PD-1/PD-L1 inhibitors (e.g., pembrolizumab, nivolumab) and CTLA-4 inhibitors (e.g., ipilimumab), are leading the market for immunotherapy drugs. These drugs work by blocking proteins that prevent immune cells from attacking cancer cells, allowing for enhanced immune responses against tumors.
Market Segmentation
The research study includes segmental analysis that divides the market into distinct groups or segments based on common characteristics. With market segmentation, businesses can identify specific customer groups that are more likely to be interested in specific products or services. Also, it enables these businesses to focus their marketing efforts and resources more efficiently, leading to higher conversion rates and improved return on investment. Furthermore, segmentation analysis helps companies develop personalized products or services, which can result in increased customer loyalty and improved customer satisfaction.
Cancer Immunotherapy Market, Type Outlook (Revenue – USD Billion, 2019-2032)
- Monoclonal Antibodies
- Cancer Vaccines
- Check Point Inhibitors & Immunomodulators
Cancer Immunotherapy Market, Application Outlook (Revenue – USD Billion, 2019-2032)
- Lung Cancer
- Breast Cancer
- Colorectal Cancer
- Melanoma
- Prostate Cancer
- Head & Neck Cancer
- Others
Cancer Immunotherapy Market, End-User Outlook (Revenue – USD Billion, 2019-2032)
- Hospitals
- Clinics
- Cancer Research Centers
Recent Developments in Cancer Immunotherapy
July 2023: Bristol Myers Squibb’s Opdivo (nivolumab) received a positive CHMP opinion for its use as an adjuvant treatment in completely resected stage IIB or IIC melanoma. If approved by the European Commission, Opdivo could become the first PD-1 inhibitor approved for use across stages IIB to IV, marking a significant milestone in the treatment of melanoma.
April 2023: Astellas Pharma Inc. announced that the U.S. FDA had approved PADCEV (enfortumab vedotin-ejfv) in combination with KEYTRUDA (pembrolizumab) for the treatment of adult patients with locally advanced or metastatic urothelial cancer (la/mUC). This approval represents an important development in the treatment of urothelial cancer, offering a new combination therapy for patients with advanced disease.
February 2023: Novartis and Dawn Health formed a strategic partnership to create a platform focused on managing chronic conditions. The collaboration aims to develop remote monitoring tools and digital services for diseases such as multiple sclerosis, hypertension, cardiovascular disease, and breast cancer. The platform will include patient apps, symptom tracking, virtual clinics, and disease-specific support, marking a step toward more personalized and accessible healthcare solutions.
The cancer immunotherapy market is growing due to the increasing incidence of cancer, the expanding effectiveness and accuracy of newer therapies, the rising adoption of target therapy, and increasing R&D activities for new drug development. Over 1,000 clinical trials for treating cancer with immune-based therapies are currently underway worldwide in various phases of development, as per the NCT Registry as of September 8, 2020. With the ongoing development of these therapies, players can expect the emergence of new and effective immunotherapies for cancer, provided trials continue to yield positive results.